Get the Stockscreener App
1.43
1.38%
-0.02
Milestone Pharmaceuticals Inc stock is traded at $1.43, with a volume of 671.57K.
It is down -1.38% in the last 24 hours and down -23.94% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.45
Open:
$1.41
24h Volume:
671.57K
Relative Volume:
0.47
Market Cap:
$76.45M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.0288
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
-9.49%
1M Performance:
-23.94%
6M Performance:
-27.41%
1Y Performance:
+2.88%
1-Day Range:
$1.40
$1.48
1-Week Range:
$1.40
$1.59
52-Week Range:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.43 | 123.20M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
How many analysts rate Milestone Pharmaceuticals Inc. as a “Buy”Wealth Building Trend Scanner That Work - jammulinksnews.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
What are the latest earnings results for Milestone Pharmaceuticals Inc.Beginner Investor Alerts For Fast Growth - jammulinksnews.com
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Trading Bots Trigger Alerts on Milestone Pharmaceuticals Inc. ActivityReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Can Milestone Pharmaceuticals Inc. hit a new high this monthSwing Setup With Technical Confirmation Explained - metal.it
RSI Suggests Rebound May Be Near in Milestone Pharmaceuticals Inc.Accurate Buy Point for Momentum Stocks Detected - metal.it
Published on: 2025-07-29 04:32:28 - beatles.ru
What are analysts’ price targets for Milestone Pharmaceuticals Inc. in the next 12 monthsConsistent wealth multiplication - jammulinksnews.com
How volatile is Milestone Pharmaceuticals Inc. stock compared to the marketGet exclusive market analysis for investors - jammulinksnews.com
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
How does Milestone Pharmaceuticals Inc. compare to its industry peersBuild wealth faster with high-performing stocks - jammulinksnews.com
Is it the right time to buy Milestone Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Milestone Pharmaceuticals Inc. stock overvalued or undervaluedSuperior returns - jammulinksnews.com
What makes Milestone Pharmaceuticals Inc. stock price move sharplyMaximize profits with strategic stock selection - jammulinksnews.com
Should I hold or sell Milestone Pharmaceuticals Inc. stock in 2025Invest smarter with high-probability setups - jammulinksnews.com
How Efficient Is Milestone Pharmaceuticals Inc. at Controlling Operating CostsFree Stock Selection - metal.it
Is Milestone Pharmaceuticals Inc. stock a good hedge against inflationFree Access to Group - metal.it
Atrial Fibrillation (AF) Pipeline Market Research Report 2025 | Insights on 10+ Companies and 12+ Drugs in the Pipeline Landscape - GlobeNewswire Inc.
Is Milestone Pharmaceuticals Inc. a good long term investmentExtraordinary earning power - PrintWeekIndia
What drives Milestone Pharmaceuticals Inc. stock priceExceptional trading results - Autocar Professional
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
Is Milestone Pharmaceuticals Inc. stock a growth or value playFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Milestone Pharmaceuticals Inc. stockConsistently superior profits - Autocar Professional
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):